Severe Malaria

Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

FP
Fosun PharmaAustralia - Sydney
1 program
1
Argesun 60mgPhase 21 trial
Active Trials
NCT05140278CompletedEst. Aug 2023
Novartis
NovartisBASEL, Switzerland
1 program
1
KAE609Phase 21 trial
Active Trials
NCT04675931Completed254Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Fosun PharmaArgesun 60mg
NovartisKAE609

Clinical Trials (2)

Total enrollment: 254 patients across 2 trials

Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate

Start: Jul 2022Est. completion: Aug 2023
Phase 2Completed

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Start: Mar 2022Est. completion: Aug 2025254 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space